AMT-130 Slows Huntington Disease Progression in Four-Year Trial Data
- Experimental gene therapy candidate ifezuntirgene inilparvovec, formerly known as AMT-130, slowed Huntington's disease progression by 44 percent at four years in an open-label Phase I/II trial, according to...
- The trial evaluated 12 patients who received the high dose of ifezuntirgene inilparvovec and reached the 48-month evaluation mark.
- Huntington's disease is an inherited, progressive genetic disorder triggered by a mutation in the HTT gene that leads to the abnormal production of the huntingtin protein.
Experimental gene therapy candidate ifezuntirgene inilparvovec, formerly known as AMT-130, slowed Huntington’s disease progression by 44 percent at four years in an open-label Phase I/II trial, according to new clinical data released by developer uniQure. While the single-administration treatment shows prolonged potential in managing the fatal neurodegenerative condition affecting roughly 7,000 individuals in Italy, researchers face complex regulatory questions as the primary endpoint failed to reach statistical significance.
Clinical Trial Data and Efficacy Metrics at Four Years
The trial evaluated 12 patients who received the high dose of ifezuntirgene inilparvovec and reached the 48-month evaluation mark. Disease progression, measured through the composite functional rating scale known as cUHDRS, slowed by 44 percent compared to an external control group drawn from the Enroll-HD database. However, this primary measure yielded a p-value of 0.144, meaning it did not meet the traditional threshold for statistical significance. By contrast, secondary endpoints demonstrated stronger signals of preservation in daily function. The Total Functional Capacity metric, which tracks a patient’s ability to maintain employment, manage daily tasks, and live independently, showed a 61 percent slowing of decline with a nominal p-value of 0.008. These figures follow an earlier analysis at 36 months across 15 high-dose patients, where the cUHDRS score showed an 80 percent statistically significant slowing.
Surgical Delivery Method and Mechanism of Action
Huntington’s disease is an inherited, progressive genetic disorder triggered by a mutation in the HTT gene that leads to the abnormal production of the huntingtin protein. Ifezuntirgene inilparvovec addresses this pathology by utilizing an adeno-associated viral vector, specifically AAV5, to deliver a custom microRNA directly into the brain cells. This genetic cargo aims to suppress the production of the toxic huntingtin protein at its source. Unlike traditional pharmaceutical interventions requiring oral administration or periodic infusions, AMT-130 is delivered via a single stereotactic neurosurgical procedure administered directly into the striatum, specifically targeting the caudate and putamen regions. Because the treatment permanently modifies the targeted brain cells, the intervention is irreversible and cannot be withdrawn once administered.
Regulatory Decisions Awaited at the FDA
UniQure formally submitted a biologics license application for AMT-130 to the U.S. Food and Drug Administration on September 2, 2026. The regulatory agency had previously indicated that the three-year data readout could serve as the foundation for an accelerated approval request. The introduction of the four-year data introduces a complex evaluation environment for regulators balancing an incurable, fatal genetic disorder against a small patient cohort and a primary endpoint that missed statistical significance. The ongoing evaluation highlights broader regulatory challenges in rare disease drug development, where traditional randomized trials involving thousands of participants remain unfeasible. The FDA proposed alternative regulatory pathways in 2026 for highly personalized therapies addressing ultra-rare conditions, offering potential frameworks for situations where standard large-scale control groups cannot be realistically maintained.